RICH
MCID: RPD005
MIFTS: 48

Rapidly Involuting Congenital Hemangioma (RICH)

Categories: Cancer diseases, Cardiovascular diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Rapidly Involuting Congenital Hemangioma

MalaCards integrated aliases for Rapidly Involuting Congenital Hemangioma:

Name: Rapidly Involuting Congenital Hemangioma 12 58
Rich 58

Characteristics:

Orphanet epidemiological data:

58
rapidly involuting congenital hemangioma
Inheritance: Not applicable; Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 12 DOID:0080895
NCIt 50 C172207
ICD10 via Orphanet 33 D18.0
UMLS via Orphanet 71 C1275421
Orphanet 58 ORPHA141184

Summaries for Rapidly Involuting Congenital Hemangioma

Disease Ontology : 12 A hemangioma that is characterized by complete regression.

MalaCards based summary : Rapidly Involuting Congenital Hemangioma, also known as rich, is related to hemangioma and congenital hemangioma. The drugs Ethanol and Borage oil have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and bone marrow, and related phenotypes are telangiectasia of the skin and subcutaneous calcification

Wikipedia : 73 A vascular tumor is a tumor of vascular origin; a soft tissue growth that can be either benign or... more...

Related Diseases for Rapidly Involuting Congenital Hemangioma

Diseases related to Rapidly Involuting Congenital Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
# Related Disease Score Top Affiliating Genes
1 hemangioma 10.9
2 congenital hemangioma 10.9
3 non-involuting congenital hemangioma 10.5
4 arteriovenous malformation 10.3
5 thrombocytopenia 10.3
6 hemangioendothelioma 10.3
7 kaposiform hemangioendothelioma 10.3
8 rare tumor 10.3
9 diaphragmatic hernia, congenital 10.2
10 thoracoabdominal syndrome 10.2
11 angioma, tufted 10.2
12 deficiency anemia 10.2
13 omphalocele 10.2
14 toxic shock syndrome 10.2
15 vascular cancer 10.2
16 teratoma 10.2
17 fibrosarcoma 10.2
18 thrombophlebitis 10.2
19 liver disease 10.2
20 congenital fibrosarcoma 10.2
21 cleft lip 10.2
22 fasciitis 10.2
23 necrotizing fasciitis 10.2
24 abdominal wall defect 10.2
25 posttransplant acute limbic encephalitis 10.2
26 rare vascular tumor 10.2

Graphical network of the top 20 diseases related to Rapidly Involuting Congenital Hemangioma:



Diseases related to Rapidly Involuting Congenital Hemangioma

Symptoms & Phenotypes for Rapidly Involuting Congenital Hemangioma

Human phenotypes related to Rapidly Involuting Congenital Hemangioma:

58 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 telangiectasia of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0100585
2 subcutaneous calcification 58 31 frequent (33%) Frequent (79-30%) HP:0007618
3 midfrontal capillary hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0007466
4 perineal hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0031449
5 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
6 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
7 peripheral arteriovenous fistula 58 31 occasional (7.5%) Occasional (29-5%) HP:0100784
8 prominent superficial veins 58 31 occasional (7.5%) Occasional (29-5%) HP:0001015
9 avascular necrosis 58 31 very rare (1%) Very rare (<4-1%) HP:0010885
10 lipoatrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0100578
11 hepatic hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0031207
12 hemangioma 58 Obligate (100%)
13 visceral hemangioma 58 Occasional (29-5%)
14 tufted angioma 58 Excluded (0%)

Drugs & Therapeutics for Rapidly Involuting Congenital Hemangioma

Drugs for Rapidly Involuting Congenital Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 534)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Borage oil Approved, Investigational Phase 4
3
Linagliptin Approved Phase 4 668270-12-0 10096344
4
Glycerol Approved, Investigational Phase 4 56-81-5 753
5
Menthol Approved Phase 4 2216-51-5 16666
6
Calcium carbonate Approved, Investigational Phase 4 471-34-1
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8 Artichoke Approved Phase 4
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
10
Allopurinol Approved Phase 4 315-30-0 2094
11
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
12
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
13
Lenograstim Approved, Investigational Phase 4 135968-09-1
14
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
15
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
16
Polyestradiol phosphate Approved Phase 4 28014-46-2
17
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
18
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
19
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
20
Febuxostat Approved Phase 4 144060-53-7 134018
21
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
22
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
23
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
26
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
27
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
28
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
29
Adenosine Approved, Investigational Phase 4 58-61-7 60961
30
Ticagrelor Approved Phase 4 274693-27-5 9871419
31
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
32
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
33
Lecithin Experimental Phase 4 8002-43-5
34
Molgramostim Investigational Phase 4 99283-10-0
35
Uric acid Investigational Phase 4 69-93-2 1175
36 Borage Phase 4
37 Dipeptidyl-Peptidase IV Inhibitors Phase 4
38 Aloe Phase 4
39 Arnica Phase 4
40 Devil's Claw Phase 4
41 Gotu Kola Phase 4
42 Antioxidants Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Antimetabolites Phase 4
45 Anticholesteremic Agents Phase 4
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
47 Hypolipidemic Agents Phase 4
48 Lipid Regulating Agents Phase 4
49 Rosuvastatin Calcium Phase 4 147098-20-2
50 Anesthetics, Dissociative Phase 4

Interventional clinical trials:

(show top 50) (show all 1219)
# Name Status NCT ID Phase Drugs
1 Application of Platelet-Rich-Plasma in Posterolateral Lumbar Fusion Unknown status NCT03779945 Phase 4
2 The Effect of Using Autologous Platelet Rich Plasma on Posterior Lumbar Interbody Fusion : a Randomized Comparative Trial Unknown status NCT03261843 Phase 4
3 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
4 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
5 Evaluation of Platelet Rich Fibrin Efficacy on Reduction of Periodontal Problems Unknown status NCT01583491 Phase 4
6 Platelet Rich Fibrin in the Treatment of Palatal Wounds After Epithelialized Free Gingival Grafts Harvesting. A Randomized Clinical Trial Unknown status NCT02438046 Phase 4
7 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
8 Effect of Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF) on Bone Regeneration in an Odontogenic Maxillary Cyst: a Randomized Clinical Trial Unknown status NCT03003013 Phase 4
9 Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Unknown status NCT02923700 Phase 4
10 Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study. Unknown status NCT01509274 Phase 4
11 Irritation and Anal Bleeding in Patients Affected by Hemorrhoids: Comparative Evaluation of Three Different Treatments. Unknown status NCT03569930 Phase 4 flavonoid-based supplements;Centella Complex
12 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
13 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
14 Socket Augmentation Using Different Platelet Concentrates, Atorvastatin Gel or Combination (Clinical and Histomorphometric Study) Completed NCT03231137 Phase 4 ATV gel
15 Adjunctive Role of Platelets Rich Fibrin in Palatal Wound Healing After Free Gingival Graft Harvesting - Case Series Completed NCT02521467 Phase 4
16 Platelet Rich Plasma (PRP) in Total Knee Replacement: A Prospective, Randomized, Single-blind, Single-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement Completed NCT00826098 Phase 4
17 The Comparison of Knee Osteoarthritis Treatment With Single-dose of Bone Marrow Aspirate Concentrate, Single-dose of Leukocyte Rich Platelet Rich Plasma and 3 Injection of High Molecular Weight Hyaluronic Acid-A Randomized Clinical Trial Completed NCT03825133 Phase 4 Hyaluronic Acid
18 Platelet Rich Fibrin (PRF) Membranes in Lateral Alveolar Ridge Augmentation. A Randomized Controlled Study Comparing an Autogenous Bone Graft Covered by a Platelet Rich Fibrin (PRF) Membrane (Test Group) or an Anorganic Bovine Bone Substitute and a Resorbable Collagen Barrier Membrane (Control Group) Completed NCT04350749 Phase 4
19 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
20 EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS Completed NCT01872455 Phase 4
21 Effects of Application Injectable Platelet-Rich Fibrin (i-PRF) as Adjunct Therapy in the Initial Treatment of Periodontitis Completed NCT04178590 Phase 4 SRP + Injectable Platelet-Rich Fibrin;SRP + placebo
22 Platelet-rich Plasma (PRP) vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial Completed NCT01670578 Phase 4
23 Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT)Combined With Intravascular Ultrasound (IVUS) Completed NCT01023607 Phase 4 Atorvastatin;Atorvastatin;Rosuvastatin
24 Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome Completed NCT03586154 Phase 4 ketamine and bupivacaine injection
25 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function Completed NCT01662414 Phase 4
26 Palatal Wound Healing Evaluation After Application of Platelet Rich Fibrin Versus 0.2% Hyaluronic Acid Dressings (Randomized Controlled Clinical Trial) Completed NCT04390100 Phase 4 hyaluronic acid (Gengiegel 0.2% oral gel )
27 Comparative Study Between Intra Articular Injection of Hyaluronic Acid (HA) With Platelet Rich Plasma (PRP) Versus Genicular Nerve Thermal Radiation in Management of Pain in Knee Osteoarthritis Completed NCT04188561 Phase 4 Intra articular injection Group
28 A Cohort Study to Evaluate the Effect of Vivostat Platelet Rich Fibrin on Diabetic Foot Ulcers. Completed NCT00770939 Phase 4
29 A Prospective Study to Analyze the Efficacy of IgM Rich Immunoglobulin as an Adjunct to Antibiotics in the Treatment of Bacterial Sepsis in Very Low Birth Weight Preterm Neonates Completed NCT03403530 Phase 4 IgM rich Immunoglobin
30 Efficacy and Safety of the Infiltration of Autologous Plasma Rich in Growth Factors (PRGF) in the Symptomatic Treatment of Knee Osteoarthritis Completed NCT00782197 Phase 4
31 The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial Completed NCT00761423 Phase 4
32 Regeneration of the Patellar Tendon After Harvesting Its Central Third With Platelet-rich Plasma. Prospective and Randomized Study. Completed NCT01111747 Phase 4
33 Arthroscopic Rotator Cuff Repair Using Standard Double Row Technique With Platelet Rich Fibrin Membrane vs. Standard Double Row Technique: A Randomized Blinded Outcomes Study Completed NCT02256891 Phase 4
34 Rosuvastatin 1.2mg in Situ Gel Combined With 1:1 Mixture of Autologous Platelet-rich Fibrin and Porus- Hydroxyappatite Bone Graft in Surgical Treatment of Mandibular Degree II Furcation Defects: A Randomized Clinical Control Trial Completed NCT02369250 Phase 4 Rosuvastatin
35 Effect of Platelet Rich Plasma ( PRP ) Applied During Knee Arthroscopy on Pain, Function and Quality of Life - A RCT With a Follow up of 12 Months Completed NCT02189408 Phase 4
36 The Efficacy of Ultrasound Guided Glenohumeral Joint Injections of Platelet Rich Plasma (PRP) Versus Hyaluronic Acid (HA) in the Treatment of Glenohumeral Osteoarthritis: a Randomized, Double-blind Control Trial Completed NCT02984228 Phase 4 Hyaluronic Acid
37 The Effect of Platelet Rich Plasma on Partial Thickness Rotator Cuff Tears: A Randomized Controlled Trial Completed NCT04743986 Phase 4 Corticosteroid (CS)
38 Efficacy of Bone Marrow Aspirate Concentrate Compared With Platelet Rich Plasma for the Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Controlled Clinical Trial Completed NCT03289416 Phase 4
39 'A Comparison of Platelet Rich Fibrin & Mineralised Freezed Dried Bone Allograft to Radiographically Evaluate Healing Post Endodontic Surgery'- an In-vivo Study Completed NCT04377698 Phase 4
40 To Evaluate the Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine as Pulpotomy Medicament in Patients With Pulpitis. Completed NCT04773886 Phase 4 Mineral trioxide aggregate;Biodentine
41 Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial Completed NCT04040309 Phase 4 Lidocaine injection
42 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
43 The Effect of Autologous Application of Platelet Rich Plasma on Wound Healing and Pain Perception After Cesarean Section in a Low Resource Setting Completed NCT04669353 Phase 4 Platelet rich plasma
44 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
45 Does Post-Operative Intra-Articular Platelet Rich Plasma Injection Improve Meniscal Repair Outcomes Completed NCT03910036 Phase 4
46 Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee. Completed NCT03086759 Phase 4 Triamcinolone Hexacetonide
47 Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial Completed NCT02401126 Phase 4
48 The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation Completed NCT02373384 Phase 4 Oral alkalinization (Potassium citrate, Allopurinol)
49 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
50 The Effect of Proprioception of Platelet Rich Plasma for Patients With Ankle Sprain Recruiting NCT03808454 Phase 4 PRP

Search NIH Clinical Center for Rapidly Involuting Congenital Hemangioma

Genetic Tests for Rapidly Involuting Congenital Hemangioma

Anatomical Context for Rapidly Involuting Congenital Hemangioma

MalaCards organs/tissues related to Rapidly Involuting Congenital Hemangioma:

40
Bone, Skin, Bone Marrow, Endothelial, Prostate, Kidney, Colon

Publications for Rapidly Involuting Congenital Hemangioma

Articles related to Rapidly Involuting Congenital Hemangioma:

(show top 50) (show all 30041)
# Title Authors PMID Year
1
Fat grafting and platelet-rich plasma in wound healing: a review of histology from animal studies. 61
33525977 2021
2
Polydopamine-modified collagen sponge scaffold as a novel dermal regeneration template with sustained release of platelet-rich plasma to accelerate skin repair: A one-step strategy. 61
33615046 2021
3
Citrus decoction by-product represents a rich source of carotenoid, phytosterol, extractable and non-extractable polyphenols. 61
33592362 2021
4
Synergistic gelling mechanism of RG-I rich citrus pectic polysaccharide at different esterification degree in calcium-induced gelation. 61
33610841 2021
5
A crucial residue in the hydrophobic core of the solenoid structure of leucine rich repeats. 61
33631375 2021
6
Nitrogen-rich covalent triazine frameworks for high-efficient removal of anion dyes and the synergistic adsorption of cationic dyes. 61
33482512 2021
7
Upcycling of PET waste into methane-rich gas and hierarchical porous carbon for high-performance supercapacitor by autogenic pressure pyrolysis and activation. 61
33578147 2021
8
The degradation behavior of calcium-rich hydroxyapatite foams in vitro. 61
32997885 2021
9
Predicting relative agronomic efficiency of phosphorus-rich organic residues. 61
33592461 2021
10
Antioxidant stability enhancement of carotenoid rich-extract from Cantaloupe melon (Cucumis melo L.) nanoencapsulated in gelatin under different storage conditions. 61
33508595 2021
11
Rapid sulfate formation from synergetic oxidation of SO2 by O3 and NO2 under ammonia-rich conditions: Implications for the explosive growth of atmospheric PM2.5 during haze events in China. 61
33770894 2021
12
Structure-regulated Ru particles decorated P-vacancy-rich CoP as a highly active and durable catalyst for NaBH4 hydrolysis. 61
33611046 2021
13
Core-shell structured monodisperse carbon-rich SiO1.31C1.46H0.81 ceramic spheres as anodes for high-capacity lithium-ion batteries. 61
33503596 2021
14
Evolution of reproductive strategies in the species-rich land snail subfamily Phaedusinae (Stylommatophora: Clausiliidae). 61
33383174 2021
15
A regenerable N-rich hierarchical porous carbon synthesized from waste biomass for H2S removal at room temperature. 61
33454487 2021
16
Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer. 61
33578234 2021
17
The lignan-rich fraction from Sambucus Williamsii Hance ameliorates dyslipidemia and insulin resistance and modulates gut microbiota composition in ovariectomized rats. 61
33761598 2021
18
Magnetic bio-activated carbons production using different process parameters for phosphorus removal from artificially prepared phosphorus-rich and domestic wastewater. 61
33453478 2021
19
Two-stage selective enzymatic hydrolysis generates protein hydrolysates rich in Asn-Pro and Ala-His for enhancing taste attributes of soy sauce. 61
33310561 2021
20
Nutrient-rich submarine groundwater discharge fuels the largest green tide in the world. 61
33736390 2021
21
A new approach for biogas slurry disposal by adopting CO2-rich biogas slurry as the flower fertilizer of Spathiphyllum: Feasibility, cost and environmental pollution potential. 61
33517019 2021
22
Laser light as a promising approach to improve the nutritional value, antioxidant capacity and anti-inflammatory activity of flavonoid-rich buckwheat sprouts. 61
33340896 2021
23
Novel sequential flow baffled microalgal-bacterial photobioreactor for enhancing nitrogen assimilation into microalgal biomass whilst bioremediating nutrient-rich wastewater simultaneously. 61
33168319 2021
24
From typical silicon-rich biomass to porous carbon-zeolite composite: A sustainable approach for efficient adsorption of CO2. 61
33454468 2021
25
Electrochemical ammonia accumulation and recovery from ammonia-rich livestock wastewater. 61
33172673 2021
26
Polyphenol-rich extract and fractions of Terminalia phaeocarpa Eichler possess hypoglycemic effect, reduce the release of cytokines, and inhibit lipase, α-glucosidase, and α-amilase enzymes. 61
33515684 2021
27
Mobilisation of hazardous elements from arsenic-rich mine drainage ochres by three Aspergillus species. 61
33450513 2021
28
Flavonoids and caffeoylquinic acids in Chrysanthemum morifolium Ramat flowers: A potentially rich source of bioactive compounds. 61
33280963 2021
29
A novel N,S-rich COF and its derived hollow N,S-doped carbon@Pd nanorods for electrochemical detection of Hg2+ and paracetamol. 61
33234399 2021
30
Efficient catalytic activity and bromate minimization over lattice oxygen-rich MnOOH nanorods in catalytic ozonation of bromide-containing organic pollutants: Lattice oxygen-directed redox cycle and bromate reduction. 61
33221077 2021
31
Peak Serum Chloride and Hyperchloremia in Patients Undergoing Cardiac Surgery Is Not Explained by Chloride-Rich Intravenous Fluid Alone: A Post-Hoc Analysis of the LICRA Trial. 61
32863142 2021
32
Removal of non-steroidal anti-inflammatory drugs from water by zeolite-rich composites: The interference of inorganic anions on the ibuprofen and naproxen adsorption. 61
33636624 2021
33
Preparation of magnetic hydrochar derived from iron-rich Phytolacca acinosa Roxb. for Cd removal. 61
33482558 2021
34
Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67. 61
32964396 2021
35
Enhanced hydrolysis of β-cypermethrin caused by deletions in the glycin-rich region of carboxylesterase 001G from Helicoverpa armigera. 61
33336552 2021
36
Effectiveness of Platelet-Rich Plasma in the Prevention of Chlamydia-Induced Hydrosalpinx in a Murine Model. 61
32989630 2021
37
Noncanonical functions of the serine-arginine-rich splicing factor (SR) family of proteins in development and disease. 61
33554347 2021
38
Insights into microbial community variability and functional genes of various Candidatus Scalindua-based anammox processes treating nitrogen-rich saline wastewater. 61
33109367 2021
39
Nanostructure of Functional Larotaxel Liposomes Decorated with Guanine-Rich Quadruplex Nucleotide-Lipid Derivative for Treatment of Resistant Breast Cancer. 61
33522108 2021
40
Autologous activated platelet-rich plasma in hair growth: A pilot study in male androgenetic alopecia with in vitro bioactivity investigation. 61
32888247 2021
41
Platelet-rich plasma lacks evidence of clinically significant improvement in androgenetic alopecia. 61
33253851 2021
42
Platelet-rich plasma has a place in the treatment of androgenetic alopecia. 61
33253835 2021
43
Randomized study of prevention of gastrointestinal toxicities by nutritional support using an amino acid-rich elemental diet during chemotherapy in patients with esophageal cancer (KDOG 1101). 61
33009977 2021
44
Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. 61
33481422 2021
45
Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity. 61
33509901 2021
46
Comparing novel versus conventional technique of platelet rich plasma therapy in periorbital hyperpigmentation: A randomized prospective split face study. 61
33793043 2021
47
Designed leucine-rich repeat proteins bind two muramyl dipeptide ligands. 61
33512005 2021
48
Efficacy of dietary nitrate-rich beetroot juice supplementation in patients with chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis. 61
33745600 2021
49
Hydrogen-rich water protects against liver injury in nonalcoholic steatohepatitis through HO-1 enhancement via IL-10 and Sirt 1 signaling. 61
33439102 2021
50
The Skin-Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein. 61
33648938 2021

Variations for Rapidly Involuting Congenital Hemangioma

Cosmic variations for Rapidly Involuting Congenital Hemangioma:

9 (show top 50) (show all 1353)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94290791 XIAP soft tissue,blood vessel,angiosarcoma,NS c.73G>C p.E25Q 23:123885735-123885735 3
2 COSM92181036 XIAP soft tissue,blood vessel,angiosarcoma,NS c.73G>C p.E25Q 23:123885735-123885735 3
3 COSM108084128 XIAP soft tissue,blood vessel,angiosarcoma,NS c.73G>C p.E25Q 23:123885735-123885735 3
4 COSM91383022 WT1 soft tissue,blood vessel,angiosarcoma,NS c.983G>A p.W328* 11:32416508-32416508 3
5 COSM148593299 WT1 soft tissue,blood vessel,angiosarcoma,NS c.983G>A p.W328* 11:32416508-32416508 3
6 COSM100781781 WT1 soft tissue,blood vessel,angiosarcoma,NS c.347G>A p.W116* 11:32416508-32416508 3
7 COSM149739973 WT1 soft tissue,blood vessel,angiosarcoma,NS c.983G>A p.W328* 11:32416508-32416508 3
8 COSM130518667 WT1 soft tissue,blood vessel,angiosarcoma,NS c.314+1069G>A p.? 11:32416508-32416508 3
9 COSM113485009 WT1 soft tissue,blood vessel,angiosarcoma,NS c.983G>A p.W328* 11:32416508-32416508 3
10 COSM111539054 WT1 soft tissue,blood vessel,angiosarcoma,NS c.950+1069G>A p.? 11:32416508-32416508 3
11 COSM147426307 WT1 soft tissue,blood vessel,angiosarcoma,NS c.950+1069G>A p.? 11:32416508-32416508 3
12 COSM149814991 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
13 COSM151514404 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4510C>T p.R1504W 16:2085245-2085245 3
14 COSM150365953 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
15 COSM151378978 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
16 COSM151755621 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
17 COSM150324884 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
18 COSM150315618 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4384C>T p.R1462W 16:2085245-2085245 3
19 COSM102634843 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
20 COSM148983289 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4387C>T p.R1463W 16:2085245-2085245 3
21 COSM101196039 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2347C>G p.H783D 16:2074338-2074338 3
22 COSM136629025 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1106G>A p.W369* 16:2060767-2060767 3
23 COSM87041278 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
24 COSM148996186 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
25 COSM150586941 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
26 COSM147712334 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
27 COSM110114858 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.962G>A p.W321* 16:2060767-2060767 3
28 COSM136619132 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4417C>T p.R1473W 16:2085245-2085245 3
29 COSM90415849 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
30 COSM151518304 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
31 COSM110120269 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2383C>G p.H795D 16:2074338-2074338 3
32 COSM149803740 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4453C>T p.R1485W 16:2085245-2085245 3
33 COSM150369517 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
34 COSM150584116 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
35 COSM110105462 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4276C>T p.R1426W 16:2085245-2085245 3
36 COSM90421077 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
37 COSM151371641 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4579C>T p.R1527W 16:2085245-2085245 3
38 COSM151519993 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
39 COSM149820498 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
40 COSM87029815 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4585C>T p.R1529W 16:2085245-2085245 3
41 COSM151748696 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4456C>T p.R1486W 16:2085245-2085245 3
42 COSM101192082 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.926G>A p.W309* 16:2060767-2060767 3
43 COSM102630453 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
44 COSM148992188 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
45 COSM147707387 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
46 COSM151376817 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
47 COSM87046601 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.2494C>G p.H832D 16:2074338-2074338 3
48 COSM147694585 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4456C>T p.R1486W 16:2085245-2085245 3
49 COSM151753419 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.1073G>A p.W358* 16:2060767-2060767 3
50 COSM101182298 TSC2 soft tissue,blood vessel,angiosarcoma,NS c.4240C>T p.R1414W 16:2085245-2085245 3

Expression for Rapidly Involuting Congenital Hemangioma

Search GEO for disease gene expression data for Rapidly Involuting Congenital Hemangioma.

Pathways for Rapidly Involuting Congenital Hemangioma

GO Terms for Rapidly Involuting Congenital Hemangioma

Sources for Rapidly Involuting Congenital Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....